Using a medication outside of its prescribed method is always risky — and in this case, especially unnecessary,” Dr. Michael Snyder told The Post.

(Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand ...

Ozempic and other GLP-1 drugs have forever altered the way people view, manage, and speak about obesity. However, it’s ...

An Ozempic injection pen on April Martin’s kitchen table on March 14, 2025. Semaglutide (GLP-1) drugs like Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on ...

The Washington Post covers efforts by insurers to clamp down on doctors prescribing Ozempic, now popular as a weight loss drug, for patients who don't evidently present with diabetes. Separately, CBS ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Mounjaro, Ozempic and other fat-melting injections have ushered in a new era in the war on obesity, but have also been linked to other health benefits, such as slashing the risk of heart attacks ...

Starting in 2022, increased demand led to shortages of semaglutide injections sold by Novo Nordisk under the brand names Ozempic and Wegovy ... instead of injector pens. “I have had direct ...

Are cookies and chips the new cigarettes? And soda, breakfast cereals and ice cream the new opioids? In his new book, “Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight ...

Rapid weight loss drugs like Ozempic can cause sagging skin and facial drooping. Surgical contouring is often the only effective solution to restore firmness and shape. There is a strange paradox ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.